Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Adial Pharmaceuticals Inc (ADIL)

Adial Pharmaceuticals Inc (ADIL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,353
  • Shares Outstanding, K 23,789
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,420 K
  • 60-Month Beta 0.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.03
Trade ADIL with:

Options Overview Details

View History
  • Implied Volatility 308.98% ( +67.57%)
  • Historical Volatility 81.82%
  • IV Percentile 96%
  • IV Rank 51.35%
  • IV High 529.07% on 03/16/22
  • IV Low 76.71% on 10/22/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 26
  • Volume Avg (30-Day) 196
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 10,284
  • Open Int (30-Day) 7,943

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.17
  • Number of Estimates 1
  • High Estimate -0.17
  • Low Estimate -0.17
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +32.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1400 +19.30%
on 05/12/22
1.7800 -23.60%
on 04/21/22
-0.3800 (-21.84%)
since 04/20/22
3-Month
1.1400 +19.30%
on 05/12/22
2.2650 -39.96%
on 04/05/22
-0.6900 (-33.66%)
since 02/18/22
52-Week
1.1400 +19.30%
on 05/12/22
5.0800 -73.23%
on 09/24/21
-1.1700 (-46.25%)
since 05/20/21

Most Recent Stories

More News
Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Diabetes and NASH

CHARLOTTESVILLE, Va., May 19, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that...

ADIL : 1.3600 (-0.73%)
ADILW : 0.3738 (+49.46%)
Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of Alcohol Use Disorder; on track to report Phase 3 results in the current...

ADIL : 1.3600 (-0.73%)
ADILW : 0.3738 (+49.46%)
Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders

CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that...

ADIL : 1.3600 (-0.73%)
ADILW : 0.3738 (+49.46%)
5 Winning Stocks Backed by the Overlooked Rising P/E Strategy

Want to try an out-of-the-box approach? Tap five stocks (GIII, PPC, TAL, ADIL and CHS) with increasing P/E ratios.

CHS : 4.32 (-2.92%)
GIII : 22.85 (-1.25%)
TAL : 4.14 (-5.91%)
ADIL : 1.3600 (-0.73%)
Adial Pharmaceuticals CEO to Participate in a Fireside Chat at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th

CHARLOTTESVILLE, Va., March 22, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage...

ADIL : 1.3600 (-0.73%)
ADILW : 0.3738 (+49.46%)
Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

CHARLOTTESVILLE, Va., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage...

ADIL : 1.3600 (-0.73%)
ADILW : 0.3738 (+49.46%)
Adial Pharmaceuticals Announces Closing of $10 Million Financing

CHARLOTTESVILLE, Va., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage...

ADIL : 1.3600 (-0.73%)
ADILW : 0.3738 (+49.46%)
Adial Pharmaceuticals Announces Pricing of $10 Million Registered Direct Offering

CHARLOTTESVILLE, Va., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage...

ADIL : 1.3600 (-0.73%)
ADILW : 0.3738 (+49.46%)
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5032 as a Potential Treatment for Asthma

CHARLOTTESVILLE, Va., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW)...

ADIL : 1.3600 (-0.73%)
ADILW : 0.3738 (+49.46%)
Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04

Patent covers patients with a specific genetic biomarker for the serotonin-3 receptor...

ADIL : 1.3600 (-0.73%)
ADILW : 0.3738 (+49.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

See More

Key Turning Points

3rd Resistance Point 1.5700
2nd Resistance Point 1.5200
1st Resistance Point 1.4400
Last Price 1.3600
1st Support Level 1.3100
2nd Support Level 1.2600
3rd Support Level 1.1800

See More

52-Week High 5.0800
Fibonacci 61.8% 3.5749
Fibonacci 50% 3.1100
Fibonacci 38.2% 2.6451
Last Price 1.3600
52-Week Low 1.1400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar